2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD

[1]  Marco Valgimigli,et al.  2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. , 2019, European heart journal.

[2]  Deepak L. Bhatt,et al.  Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. , 2019, The lancet. Diabetes & endocrinology.

[3]  W. E. Sanabria,et al.  Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial , 2019, The Lancet.

[4]  S. Schneeweiss,et al.  Fracture Risk After Initiation of Use of Canagliflozin , 2019, Annals of Internal Medicine.

[5]  N. Sattar,et al.  Age at Diagnosis of Type 2 Diabetes Mellitus and Associations With Cardiovascular and Mortality Risks: Findings From the Swedish National Diabetes Registry , 2019, Circulation.

[6]  Angela M Rodrigues,et al.  Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. , 2019, The lancet. Diabetes & endocrinology.

[7]  Marc P. Bonaca,et al.  Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials , 2019, Circulation.

[8]  B. Zinman,et al.  Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. , 2019, The New England journal of medicine.

[9]  Antonio Ceriello,et al.  Glycaemic variability in diabetes: clinical and therapeutic implications. , 2019, The lancet. Diabetes & endocrinology.

[10]  J. Pepper,et al.  Bilateral versus Single Internal‐Thoracic‐Artery Grafts at 10 Years , 2019, The New England journal of medicine.

[11]  Declare–Timi Investigators.  Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes , 2019 .

[12]  Carmelina Investigators.  Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA , 2019 .

[13]  Deepak L. Bhatt,et al.  Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia , 2019, The New England journal of medicine.

[14]  M. Pencina,et al.  Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial , 2019, JAMA.

[15]  Marc P. Bonaca,et al.  SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials , 2019, The Lancet.

[16]  P. Seferovic,et al.  Long-term mortality is increased in patients with undetected prediabetes and type-2 diabetes hospitalized for worsening heart failure and reduced ejection fraction , 2018, European journal of preventive cardiology.

[17]  N. Marx,et al.  Cardiovascular protection in type 2 diabetes: Insights from recent outcome trials , 2018, Diabetes, obesity & metabolism.

[18]  B. Balkau,et al.  Haemoglobin A1c and 5-year all-cause mortality in French type 2 diabetic patients aged 70 years and older: The GERODIAB observational cohort. , 2018, Diabetes & metabolism.

[19]  Odyssey Outcomes Investigators.  Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome , 2018 .

[20]  R. Collins,et al.  Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus , 2018, The New England journal of medicine.

[21]  R. Collins,et al.  Effects of n‐3 Fatty Acid Supplements in Diabetes Mellitus , 2018, The New England journal of medicine.

[22]  G. Filippatos,et al.  Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association–European Society of Cardiology , 2018, European heart journal.

[23]  Diane M. Miller,et al.  Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. , 2018, Lancet.

[24]  I. Shimomura,et al.  Clinical Utility of Carotid Ultrasonography in the Prediction of Cardiovascular Events in Patients with Diabetes: A Combined Analysis of Data Obtained in Five Longitudinal Studies , 2018, Journal of atherosclerosis and thrombosis.

[25]  L. Rydén,et al.  Type 2 diabetes and heart failure: Characteristics and prognosis in preserved, mid-range and reduced ventricular function , 2018, Diabetes & vascular disease research.

[26]  P. Rothwell,et al.  Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial , 2018, The Lancet.

[27]  G. Lip,et al.  2018 ESC/ESH Guidelines for the management of arterial hypertension. , 2018, European heart journal.

[28]  Björn Eliasson,et al.  Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes , 2018, The New England journal of medicine.

[29]  Jennifer Y. Liu,et al.  The Legacy Effect in Type 2 Diabetes: Impact of Early Glycemic Control on Future Complications (The Diabetes & Aging Study) , 2018, Diabetes Care.

[30]  A. Hattersley,et al.  Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study , 2018, The Lancet.

[31]  N. Cook,et al.  Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials , 2018, The Lancet.

[32]  J. Stehli,et al.  Non-invasive screening for coronary artery disease in asymptomatic diabetic patients: a systematic review and meta-analysis of randomised controlled trials , 2018, European Heart Journal-Cardiovascular Imaging.

[33]  R. Collins,et al.  Sex-specific relevance of diabetes to occlusive vascular and other mortality : a collaborative meta-analysis of individual data from 980 793 adults from 68 prospective studies , 2019 .

[34]  Mohammed K. Ali,et al.  Global Diabetes Prevention Interventions: A Systematic Review and Network Meta-analysis of the Real-World Impact on Incidence, Weight, and Glucose , 2018, Diabetes Care.

[35]  M. Hernán,et al.  Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra‐Virgin Olive Oil or Nuts , 2018, The New England journal of medicine.

[36]  S. Zick,et al.  Diets for Health: Goals and Guidelines. , 2018, American family physician.

[37]  K. Khunti,et al.  Association of hypoglycaemia and risk of cardiac arrhythmia in patients with diabetes mellitus: A systematic review and meta‐analysis , 2018, Diabetes, obesity & metabolism.

[38]  O. Pedersen,et al.  Reduced risk of heart failure with intensified multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: 21 years of follow-up in the randomised Steno-2 study , 2018, Diabetologia.

[39]  M. Gulati,et al.  Socioeconomic Status and Cardiovascular Outcomes: Challenges and Interventions , 2018, Circulation.

[40]  E. Grove,et al.  Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis. , 2018, European heart journal.

[41]  T. Takken,et al.  Exercise Prescription in Patients with Different Combinations of Cardiovascular Disease Risk Factors: A Consensus Statement from the EXPERT Working Group , 2018, Sports Medicine.

[42]  K. Filion,et al.  Smoking Cessation in Patients With Acute Coronary Syndrome. , 2018, The American journal of cardiology.

[43]  G. Angelini,et al.  Radial‐Artery or Saphenous‐Vein Grafts in Coronary‐Artery Bypass Surgery , 2018, The New England journal of medicine.

[44]  William J. Astle,et al.  Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies , 2018, The Lancet.

[45]  R. Giugliano,et al.  Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes Vytorin Efficacy International Trial) , 2018, Circulation.

[46]  V. Fuster,et al.  Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data , 2018, The Lancet.

[47]  Karim Ladha,et al.  Efficacy of self-monitored blood pressure, with or without telemonitoring, for titration of antihypertensive medication (TASMINH4): an unmasked randomised controlled trial , 2018, The Lancet.

[48]  G. Filippatos,et al.  Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology , 2018, European journal of heart failure.

[49]  P. Doherty,et al.  An analysis of barriers to entry of cardiac rehabilitation in patients with diabetes: Using data from the National Audit of Cardiac Rehabilitation , 2018, Diabetes & vascular disease research.

[50]  F. McAlister,et al.  Coronary Artery Bypass Surgery Improves Outcomes in Patients With Diabetes and Left Ventricular Dysfunction. , 2018, Journal of the American College of Cardiology.

[51]  R. Hunt,et al.  Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials , 2018, The lancet. Gastroenterology & hepatology.

[52]  M. Kivimäki,et al.  Risk of Cardiovascular Disease and Death in Individuals With Prediabetes Defined by Different Criteria: The Whitehall II Study , 2018, Diabetes Care.

[53]  V. Chuter,et al.  Diagnostic accuracy of the postexercise ankle–brachial index for detecting peripheral artery disease in suspected claudicants with and without diabetes , 2018, Vascular medicine.

[54]  K. Eeg-Olofsson,et al.  Characteristics and Prognosis in Women and Men With Type 1 Diabetes Undergoing Coronary Angiography: A Nationwide Registry Report , 2018, Diabetes Care.

[55]  J. Tuomilehto,et al.  Undetected dysglycaemia common in primary care patients treated for hypertension and/or dyslipidaemia: on the need for a screening strategy in clinical practice. A report from EUROASPIRE IV a registry from the EuroObservational Research Programme of the European Society of Cardiology , 2018, Cardiovascular Diabetology.

[56]  Marco Valgimigli,et al.  2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). , 2018, European heart journal.

[57]  G. Filippatos,et al.  Renin inhibition in heart failure and diabetes: the real story , 2018, European journal of heart failure.

[58]  F. D’Ascenzo,et al.  Unmeasured Confounders in Observational Studies Comparing Bilateral Versus Single Internal Thoracic Artery for Coronary Artery Bypass Grafting: A Meta‐Analysis , 2018, Journal of the American Heart Association.

[59]  Roy Taylor,et al.  Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial , 2017, The Lancet.

[60]  R. Collins,et al.  ASCEND: A Study of Cardiovascular Events iN Diabetes: Characteristics of a randomized trial of aspirin and of omega-3 fatty acid supplementation in 15,480 people with diabetes , 2017, American heart journal.

[61]  K. Mahaffey,et al.  Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events , 2017, Circulation.

[62]  Khalid Yusoff,et al.  Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. , 2017, Lancet.

[63]  B. Gilbert,et al.  Antihyperglycemic and Metabolic Effects of Ranolazine in Patients With Diabetes Mellitus. , 2017, The American journal of cardiology.

[64]  A. Fabbro,et al.  Effectiveness of individual strategies for the empowerment of patients with diabetes mellitus: A systematic review with meta-analysis. , 2017, Primary care diabetes.

[65]  P. Kolh,et al.  2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. , 2018, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[66]  J. Dunning,et al.  2017 EACTS Guidelines on perioperative medication in adult cardiac surgery. , 2018, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[67]  P. Ponikowski,et al.  Effects of Vildagliptin on Ventricular Function in Patients With Type 2 Diabetes Mellitus and Heart Failure: A Randomized Placebo-Controlled Trial. , 2018, JACC. Heart failure.

[68]  A Ross Naylor,et al.  2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed b , 2018, European heart journal.

[69]  S. Verma,et al.  Surgical Versus Percutaneous Coronary Revascularization in Patients With Diabetes and Acute Coronary Syndromes. , 2017, Journal of the American College of Cardiology.

[70]  B. Zinman,et al.  The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics , 2017, American Journal of Nephrology.

[71]  Lawrence A Leiter,et al.  Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. , 2017, The lancet. Diabetes & endocrinology.

[72]  Roberto Ferrari,et al.  Epidemiology and one‐year outcomes in patients with chronic heart failure and preserved, mid‐range and reduced ejection fraction: an analysis of the ESC Heart Failure Long‐Term Registry , 2017, European journal of heart failure.

[73]  Y. Ohashi,et al.  Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial. , 2017, The lancet. Diabetes & endocrinology.

[74]  Eyal Dassau,et al.  International Consensus on Use of Continuous Glucose Monitoring , 2017, Diabetes Care.

[75]  B. Gaszner,et al.  Effectiveness and safety of anti-ischemic trimetazidine in patients with stable angina pectoris and Type 2 diabetes. , 2017, Journal of comparative effectiveness research.

[76]  H. Parving,et al.  Plasma high-sensitivity troponin T predicts end-stage renal disease and cardiovascular and all-cause mortality in patients with type 1 diabetes and diabetic nephropathy. , 2017, Kidney international.

[77]  T. Greenhalgh,et al.  Preventing type 2 diabetes: systematic review of studies of cost-effectiveness of lifestyle programmes and metformin, with and without screening, for pre-diabetes , 2017, BMJ Open.

[78]  R. Holman,et al.  Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. , 2017, The lancet. Diabetes & endocrinology.

[79]  M. Boemi,et al.  Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. , 2017, The lancet. Diabetes & endocrinology.

[80]  Lawrence A Leiter,et al.  Efficacy and safety of alirocumab in insulin‐treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM‐INSULIN randomized trial , 2017, Diabetes, obesity & metabolism.

[81]  C. Patrono,et al.  Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis. , 2017, Journal of the American College of Cardiology.

[82]  C. Jellis,et al.  Clinical Implications of Echocardiographic Phenotypes of Patients With Diabetes Mellitus. , 2017, Journal of the American College of Cardiology.

[83]  K. Goel,et al.  Benefits of Cardiac Rehabilitation on Cardiovascular Outcomes in Patients With Diabetes Mellitus After Percutaneous Coronary Intervention , 2017, Journal of the American Heart Association.

[84]  H. Schunkert,et al.  Percutaneous Coronary Intervention vs Coronary Artery Bypass Grafting in Patients With Left Main Coronary Artery Stenosis: A Systematic Review and Meta-analysis , 2017, JAMA cardiology.

[85]  Alison B. Evert,et al.  Academy of Nutrition and Dietetics Nutrition Practice Guideline for Type 1 and Type 2 Diabetes in Adults: Nutrition Intervention Evidence Reviews and Recommendations. , 2017, Journal of the Academy of Nutrition and Dietetics.

[86]  F. Zaccardi,et al.  Platelet indices and glucose control in type 1 and type 2 diabetes mellitus: A case-control study. , 2017, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[87]  K. Watson,et al.  Statin use and risk of developing diabetes: results from the Diabetes Prevention Program , 2017, BMJ Open Diabetes Research & Care.

[88]  A. Chait,et al.  Treatment of Dyslipidemia in Diabetes: Recent Advances and Remaining Questions , 2017, Current Diabetes Reports.

[89]  B. Zinman,et al.  Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2) , 2017, Diabetologia.

[90]  B. Zinman,et al.  DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality , 2017, Diabetologia.

[91]  Neha J. Pagidipati,et al.  Effects of Once‐Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes , 2017, The New England journal of medicine.

[92]  J. McMurray,et al.  The Metabolodiuretic Promise of Sodium-Dependent Glucose Cotransporter 2 Inhibition: The Search for the Sweet Spot in Heart Failure. , 2017, JAMA cardiology.

[93]  N. Sattar,et al.  Comparison of non-traditional biomarkers, and combinations of biomarkers, for vascular risk prediction in people with type 2 diabetes: The Edinburgh Type 2 Diabetes Study , 2017, Atherosclerosis.

[94]  B. Zinman,et al.  Liraglutide and Renal Outcomes in Type 2 Diabetes , 2017, The New England journal of medicine.

[95]  D. Drucker,et al.  Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors , 2017, Circulation.

[96]  Deepak L. Bhatt,et al.  Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease , 2017, The New England journal of medicine.

[97]  E. Vicaut,et al.  Optimal timing of an invasive strategy in patients with non-ST-elevation acute coronary syndrome: a meta-analysis of randomised trials , 2017, The Lancet.

[98]  J. Franklin,et al.  Effect of US Food and Drug Administration's Cardiovascular Safety Guidance on Diabetes Drug Development , 2017, Clinical pharmacology and therapeutics.

[99]  L. Ball,et al.  Systematic Review or Meta-analysis Effectiveness of group-based self-management education for individuals with Type 2 diabetes: a systematic review with meta-analyses and meta-regression , 2017 .

[100]  Jennifer B. Green,et al.  Cardiovascular Outcome Trial Update in Diabetes: New Evidence, Remaining Questions , 2017, Current Diabetes Reports.

[101]  Michael Miller,et al.  Dietary Fats and Cardiovascular Disease: A Presidential Advisory From the American Heart Association , 2017, Circulation.

[102]  Biao Xu,et al.  Long-term efficacy and safety of carotid artery stenting versus endarterectomy: A meta-analysis of randomized controlled trials , 2017, PloS one.

[103]  S. Yusuf,et al.  Prognostic Impact of Diabetes and Prediabetes on Survival Outcomes in Patients With Chronic Heart Failure: A Post‐Hoc Analysis of the GISSI‐HF (Gruppo Italiano per lo Studio della Sopravvivenza nella Insufficienza Cardiaca‐Heart Failure) Trial , 2017, Journal of the American Heart Association.

[104]  J. Tuomilehto,et al.  The Prognostic Value of Fasting Plasma Glucose, Two-Hour Postload Glucose, and HbA1c in Patients With Coronary Artery Disease: A Report From EUROASPIRE IV , 2017, Diabetes Care.

[105]  K. Mahaffey,et al.  Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes , 2017, The New England journal of medicine.

[106]  B. Zinman,et al.  Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes , 2017, The New England journal of medicine.

[107]  V. Coates,et al.  An evaluation of the effectiveness of self‐management interventions for people with type 2 diabetes after an acute coronary syndrome: a systematic review , 2017, Journal of clinical nursing.

[108]  A. Kengne,et al.  Effect of Sodium‐Glucose Cotransport‐2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta‐Analysis of 43 Randomized Control Trials With 22 528 Patients , 2017, Journal of the American Heart Association.

[109]  Quanmin Jing,et al.  The effect of trimetazidine treatment in patients with type 2 diabetes undergoing percutaneous coronary intervention for AMI , 2017, The American journal of emergency medicine.

[110]  M. Shapiro,et al.  Risk of Cardiovascular Events in Patients With Diabetes Mellitus on β-Blockers , 2017, Hypertension.

[111]  Tong Li,et al.  Smoking prevalence and attributable disease burden in 195 countries and territories, 1990–2015: a systematic analysis from the Global Burden of Disease Study 2015 , 2017, The Lancet.

[112]  Akshay S. Desai,et al.  Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. , 2017, The lancet. Diabetes & endocrinology.

[113]  J Chau,et al.  Systematic review on the cost-effectiveness of self-management education programme for type 2 diabetes mellitus. , 2017, Diabetes research and clinical practice.

[114]  G. Parati,et al.  Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10 – Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials , 2017, Journal of hypertension.

[115]  S. Harding,et al.  The Effectiveness of Lifestyle Adaptation for the Prevention of Prediabetes in Adults: A Systematic Review , 2017, Journal of diabetes research.

[116]  O. Pedersen,et al.  Intensified multifactorial intervention in type 2 diabetics with microalbuminuria leads to long-term renal benefits. , 2017, Kidney international.

[117]  Mei-Fang Chen,et al.  Empowerment Program for People With Prediabetes: A Randomized Controlled Trial , 2017, The journal of nursing research : JNR.

[118]  A. Keech,et al.  Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease , 2017, The New England journal of medicine.

[119]  R. Ajjan,et al.  Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk , 2017, Cardiovascular Diabetology.

[120]  K. Khunti,et al.  Cardiovascular events and all‐cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: A Bayesian meta‐analysis of survival data , 2017, Diabetes, obesity & metabolism.

[121]  Samin K. Sharma,et al.  Efficacy and safety of everolimus and zotarolimus-eluting stents versus first-generation drug-eluting stents in patients with diabetes: A meta-analysis of randomized trials. , 2017, International journal of cardiology.

[122]  A. Astrup,et al.  Systematic review and meta-analysis of dietary carbohydrate restriction in patients with type 2 diabetes , 2017, BMJ Open Diabetes Research and Care.

[123]  K. Mahaffey,et al.  Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study–Renal (CANVAS‐R): A randomized, placebo‐controlled trial , 2017, Diabetes, obesity & metabolism.

[124]  R. McKelvie,et al.  Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction) , 2017, Circulation.

[125]  T. Greenhalgh,et al.  Efficacy and effectiveness of screen and treat policies in prevention of type 2 diabetes: systematic review and meta-analysis of screening tests and interventions , 2017, British Medical Journal.

[126]  O. Hamdy,et al.  Long-term effect of intensive lifestyle intervention on cardiovascular risk factors in patients with diabetes in real-world clinical practice: a 5-year longitudinal study , 2017, BMJ Open Diabetes Research and Care.

[127]  H. Muderrisoğlu,et al.  Effects of Carvedilol Compared to Nebivolol on Insulin Resistance and Lipid Profile in Patients With Essential Hypertension , 2017, Journal of cardiovascular pharmacology and therapeutics.

[128]  L. Tarnow,et al.  Effect of liraglutide, a glucagon‐like peptide‐1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)—a multicentre, double‐blind, randomised, placebo‐controlled trial , 2017, European journal of heart failure.

[129]  T. Morimoto,et al.  Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: 10-Year Follow-Up of a Randomized Controlled Trial , 2016, Circulation.

[130]  G. Filippatos,et al.  Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside. , 2017, Handbook of experimental pharmacology.

[131]  V. Vallon,et al.  Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition , 2017, Diabetologia.

[132]  Gerry Rayman,et al.  Flash Glucose-Sensing Technology as a Replacement for Blood Glucose Monitoring for the Management of Insulin-Treated Type 2 Diabetes: a Multicenter, Open-Label Randomized Controlled Trial , 2016, Diabetes Therapy.

[133]  A. Kelly,et al.  Cardiovascular effects of bariatric surgery , 2016, Nature Reviews Cardiology.

[134]  O. Franco,et al.  Prevalence and Prognostic Implications of Coronary Artery Calcification in Low-Risk Women: A Meta-analysis. , 2016, JAMA.

[135]  Darren K Mcguire,et al.  Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus. , 2016, European heart journal.

[136]  P. Geelhoed-Duijvestijn,et al.  Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial , 2016, The Lancet.

[137]  S. Pocock,et al.  Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease. , 2016, The New England journal of medicine.

[138]  P. Ponikowski,et al.  [2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure]. , 2016, Kardiologia polska.

[139]  D. Dunstan,et al.  Physical Activity/Exercise and Diabetes: A Position Statement of the American Diabetes Association , 2016, Diabetes Care.

[140]  T. Wilt,et al.  Effects on Health Outcomes of a Mediterranean Diet With No Restriction on Fat Intake , 2016, Annals of Internal Medicine.

[141]  L. Rydén,et al.  Prognostic Implications of Type 2 Diabetes Mellitus in Ischemic and Nonischemic Heart Failure. , 2016, Journal of the American College of Cardiology.

[142]  Lawrence A Leiter,et al.  Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. , 2016, The New England journal of medicine.

[143]  P. Serruys,et al.  Outcomes After Percutaneous Coronary Intervention or Bypass Surgery in Patients With Unprotected Left Main Disease. , 2016, Journal of the American College of Cardiology.

[144]  Hans Eiskjær,et al.  Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure. , 2016, The New England journal of medicine.

[145]  P. Kirchhof,et al.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, European heart journal.

[146]  O. Pedersen,et al.  Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial , 2016, Diabetologia.

[147]  J. Eriksson,et al.  Sulphonylurea compared to DPP-4 inhibitors in combination with metformin carries increased risk of severe hypoglycemia, cardiovascular events, and all-cause mortality. , 2016, Diabetes research and clinical practice.

[148]  G. Filippatos,et al.  Reframing the association and significance of co‐morbidities in heart failure , 2016, European journal of heart failure.

[149]  Deepak L. Bhatt,et al.  Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS-TIMI 54. , 2016, Journal of the American College of Cardiology.

[150]  John M Lachin,et al.  Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. , 2016, The New England journal of medicine.

[151]  John B Buse,et al.  Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. , 2016, The New England journal of medicine.

[152]  Sheyu Li,et al.  Intensive walking exercise for lower extremity peripheral arterial disease: A systematic review and meta‐analysis , 2016, Journal of diabetes.

[153]  P. Ponikowski,et al.  A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease , 2016, European heart journal.

[154]  J. McMurray,et al.  SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms? , 2016, Diabetologia.

[155]  C. Ballantyne,et al.  Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial. , 2016, JAMA.

[156]  S. Hutfless,et al.  Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes , 2016, Annals of Internal Medicine.

[157]  J. McMurray,et al.  Efficacy and safety of digoxin in patients with heart failure and reduced ejection fraction according to diabetes status: An analysis of the Digitalis Investigation Group (DIG) trial. , 2016, International journal of cardiology.

[158]  P. Poole‐Wilson,et al.  WITHDRAWN: Diuretics for heart failure. , 2016, The Cochrane database of systematic reviews.

[159]  J. Rouleau,et al.  Coronary-Artery Bypass Surgery in Patients with Ischemic Cardiomyopathy. , 2016, The New England journal of medicine.

[160]  A. Schjerning,et al.  Risk of atrial fibrillation in diabetes mellitus: A nationwide cohort study , 2016, European journal of preventive cardiology.

[161]  M. Al-Omran,et al.  Impact of diabetes on carotid artery revascularization. , 2016, Journal of vascular surgery.

[162]  S. Bakker,et al.  High-sensitive troponin T is associated with all-cause and cardiovascular mortality in stable outpatients with type 2 diabetes (ZODIAC-37). , 2016, American heart journal.

[163]  J. Gross,et al.  The Association between Sulfonylurea Use and All-Cause and Cardiovascular Mortality: A Meta-Analysis with Trial Sequential Analysis of Randomized Clinical Trials , 2016, PLoS medicine.

[164]  M. Woodward,et al.  Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON , 2016, Diabetes Care.

[165]  Connie M. Rhee,et al.  US Renal Data System 2015 Annual Data Report: Epidemiology of Kidney Disease in the United States. , 2016, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[166]  D. Tanné,et al.  Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. , 2016, The New England journal of medicine.

[167]  R. Holman,et al.  Randomized controlled trial comparing impact on platelet reactivity of twice‐daily with once‐daily aspirin in people with Type 2 diabetes , 2016, Diabetic medicine : a journal of the British Diabetic Association.

[168]  P. Serruys,et al.  Impact of Diabetic Status on Outcomes After Revascularization With Drug-Eluting Stents in Relation to Coronary Artery Disease Complexity: Patient-Level Pooled Analysis of 6081 Patients , 2016, Circulation. Cardiovascular interventions.

[169]  T. Callister,et al.  Absence of Coronary Artery Calcium Identifies Asymptomatic Diabetic Individuals at Low Near-Term But Not Long-Term Risk of Mortality: A 15-Year Follow-Up Study of 9715 Patients , 2016, Circulation. Cardiovascular imaging.

[170]  M. Woodward,et al.  Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis , 2016, The Lancet.

[171]  B. Zinman,et al.  Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial , 2016, European heart journal.

[172]  J. Reekers,et al.  Effectiveness of revascularization of the ulcerated foot in patients with diabetes and peripheral artery disease: a systematic review , 2016, Diabetes/metabolism research and reviews.

[173]  Akshay S. Desai,et al.  Risk Related to Pre–Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction , 2016, Circulation. Heart failure.

[174]  T. Kawasaki,et al.  Usefulness of carotid plaque (sum and maximum of plaque thickness) in combination with intima‐media thickness for the detection of coronary artery disease in asymptomatic patients with diabetes , 2015, Journal of diabetes investigation.

[175]  Jeroen J. Bax,et al.  2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). , 2011, European heart journal.

[176]  Daniel J Cox,et al.  Glycemic load, exercise, and monitoring blood glucose (GEM): A paradigm shift in the treatment of type 2 diabetes mellitus. , 2016, Diabetes research and clinical practice.

[177]  A. Hoes,et al.  2016 European Guidelines on cardiovascular disease prevention in clinical practice. , 2016, Revista espanola de cardiologia.

[178]  Andrea Giustina,et al.  The role of patient education in the prevention and management of type 2 diabetes: an overview , 2016, Endocrine.

[179]  S. Solomon,et al.  Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. , 2015, The New England journal of medicine.

[180]  P. Herbison,et al.  Has the difference in mortality between percutaneous coronary intervention and coronary artery bypass grafting in people with heart disease and diabetes changed over the years? A systematic review and meta-regression , 2015, BMJ Open.

[181]  B. Zinman,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2015, The New England journal of medicine.

[182]  R. Roussel,et al.  Overview of Data Concerning the Safe Use of Antihyperglycemic Medications in Type 2 Diabetes Mellitus and Chronic Kidney Disease , 2015, Advances in Therapy.

[183]  D. Mikhailidis,et al.  Abdominal aortic aneurysms and diabetes mellitus. , 2015, Journal of diabetes and its complications.

[184]  A. Rosengren,et al.  Excess Mortality among Persons with Type 2 Diabetes. , 2015, The New England journal of medicine.

[185]  C. Patrono,et al.  In Vivo Platelet Activation and Aspirin Responsiveness in Type 1 Diabetes , 2015, Diabetes.

[186]  Y. Gan,et al.  The Health Effects of Passive Smoking: An Overview of Systematic Reviews Based on Observational Epidemiological Evidence , 2015, PloS one.

[187]  J. De Sutter,et al.  Patients with coronary artery disease and diabetes need improved management: a report from the EUROASPIRE IV survey: a registry from the EuroObservational Research Programme of the European Society of Cardiology , 2015, Cardiovascular Diabetology.

[188]  P. Remington,et al.  Combined Diet and Physical Activity Promotion Programs to Prevent Type 2 Diabetes Among Persons at Increased Risk: A Systematic Review for the Community Preventive Services Task Force , 2015, Annals of Internal Medicine.

[189]  Deepak L. Bhatt,et al.  Impact of Diabetes Mellitus on Hospitalization for Heart Failure, Cardiovascular Events, and Death: Outcomes at 4 Years From the Reduction of Atherothrombosis for Continued Health (REACH) Registry , 2015, Circulation.

[190]  J. Boucher,et al.  Lifestyle weight-loss intervention outcomes in overweight and obese adults with type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials. , 2015, Journal of the Academy of Nutrition and Dietetics.

[191]  M. Pencina,et al.  Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. , 2015, The New England journal of medicine.

[192]  W. Paulus,et al.  Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes. , 2015, European heart journal.

[193]  A. Avogaro,et al.  Carotid Plaque Calcification Predicts Future Cardiovascular Events in Type 2 Diabetes , 2015, Diabetes Care.

[194]  E. Hannan,et al.  Everolimus Eluting Stents Versus Coronary Artery Bypass Graft Surgery for Patients With Diabetes Mellitus and Multivessel Disease , 2015, Circulation. Cardiovascular interventions.

[195]  C. Quinn,et al.  CONSORT-EHEALTH Checklist V1.6.2 Report , 2015 .

[196]  Improve-It Investigators.  Ezetimibe added to statin therapy after acute coronary syndromes , 2015 .

[197]  M. Jeong,et al.  Randomized Trial of Stents Versus Bypass Surgery for Left Main Coronary Artery Disease: 5-Year Outcomes of the PRECOMBAT Study. , 2015, Journal of the American College of Cardiology.

[198]  J. Tuomilehto,et al.  Screening for dysglycaemia in patients with coronary artery disease as reflected by fasting glucose, oral glucose tolerance test, and HbA1c: a report from EUROASPIRE IV--a survey from the European Society of Cardiology. , 2015, European heart journal.

[199]  P. Valensi,et al.  Evidence for a Specific Diabetic Cardiomyopathy: An Observational Retrospective Echocardiographic Study in 656 Asymptomatic Type 2 Diabetic Patients , 2015, International journal of endocrinology.

[200]  Marc P. Bonaca,et al.  Long-term use of ticagrelor in patients with prior myocardial infarction. , 2015, The New England journal of medicine.

[201]  Dario Pitocco,et al.  Platelet mean volume, distribution width, and count in type 2 diabetes, impaired fasting glucose, and metabolic syndrome: a meta‐analysis , 2015, Diabetes/metabolism research and reviews.

[202]  V. Aboyans,et al.  Epidemiology of peripheral artery disease. , 2015, Circulation research.

[203]  Barry J. Davis,et al.  Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials , 2015, The Lancet.

[204]  E. Hannan,et al.  Everolimus-eluting stents or bypass surgery for multivessel coronary disease. , 2015, The New England journal of medicine.

[205]  A. Yeung,et al.  Trial of everolimus-eluting stents or bypass surgery for coronary disease. , 2015, The New England journal of medicine.

[206]  S. Hernández-Díaz,et al.  Statins and congenital malformations: cohort study , 2015, BMJ : British Medical Journal.

[207]  Michael E. Hall,et al.  Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. , 2015, Circulation research.

[208]  Rafael Perera,et al.  Personalised care planning for adults with chronic or long-term health conditions. , 2015, The Cochrane database of systematic reviews.

[209]  F. Hadaegh,et al.  Silent coronary artery disease and incidence of cardiovascular and mortality events at different levels of glucose regulation; results of greater than a decade follow-up. , 2015, International journal of cardiology.

[210]  M. Prins,et al.  Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery. , 2015, The Cochrane database of systematic reviews.

[211]  K. Rahimi,et al.  Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. , 2015, JAMA.

[212]  J. Kuang,et al.  Effect of lifestyle intervention in patients with type 2 diabetes: a meta-analysis. , 2015, Metabolism: clinical and experimental.

[213]  K. Malmberg,et al.  Sustained prognostic implications of newly detected glucose abnormalities in patients with acute myocardial infarction: Long-term follow-up of the Glucose Tolerance in Patients with Acute Myocardial Infarction cohort , 2015, Diabetes & vascular disease research.

[214]  J. Rouleau,et al.  Clinical characteristics and outcomes of patients with and without diabetes in the Surgical Treatment for Ischemic Heart Failure (STICH) trial , 2014, European journal of heart failure.

[215]  Andrea Mazzanti,et al.  [2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death]. , 2015, Kardiologia polska.

[216]  H. May,et al.  Effect of screening for coronary artery disease using CT angiography on mortality and cardiac events in high-risk patients with diabetes: the FACTOR-64 randomized clinical trial. , 2014, JAMA.

[217]  Braunwald,et al.  Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. , 2014, The New England journal of medicine.

[218]  P. Valensi,et al.  Increased glycemic variability and decrease of the postprandial glucose contribution to HbA1c in obese subjects across the glycemic continuum from normal glycemia to first time diagnosed diabetes. , 2014, Metabolism: clinical and experimental.

[219]  Samin K. Sharma,et al.  Coronary artery bypass graft surgery versus drug-eluting stents for patients with isolated proximal left anterior descending disease. , 2014, Journal of the American College of Cardiology.

[220]  Origin Trial Investigators.  Predictors of Nonsevere and Severe Hypoglycemia During Glucose-Lowering Treatment With Insulin Glargine or Standard Drugs in the ORIGIN Trial , 2014, Diabetes Care.

[221]  Deepak L. Bhatt,et al.  Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial , 2014, Circulation.

[222]  M. Mack,et al.  Coronary artery bypass grafting vs. percutaneous coronary intervention for patients with three-vessel disease: final five-year follow-up of the SYNTAX trial. , 2014, European heart journal.

[223]  M. Woodward,et al.  Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. , 2014, The New England journal of medicine.

[224]  J. Spertus,et al.  Prevalence of glucose abnormalities among patients presenting with an acute myocardial infarction. , 2014, American heart journal.

[225]  M. Pfisterer,et al.  Progression to overt or silent CAD in asymptomatic patients with diabetes mellitus at high coronary risk: main findings of the prospective multicenter BARDOT trial with a pilot randomized treatment substudy. , 2014, JACC. Cardiovascular imaging.

[226]  V. Fuster,et al.  Long-term outcome of PCI versus CABG in insulin and non-insulin-treated diabetic patients: results from the FREEDOM trial. , 2014, Journal of the American College of Cardiology.

[227]  Akshay S. Desai,et al.  Angiotensin-neprilysin inhibition versus enalapril in heart failure. , 2014, The New England journal of medicine.

[228]  N. White,et al.  Effect of Intensive Diabetes Therapy on the Progression of Diabetic Retinopathy in Patients With Type 1 Diabetes: 18 Years of Follow-up in the DCCT/EDIC , 2014, Diabetes.

[229]  John Sapp,et al.  EHRA/HRS/APHRS expert consensus on ventricular arrhythmias , 2014, Heart rhythm.

[230]  V. Zoffmann,et al.  Effect of guided self-determination youth intervention integrated into outpatient visits versus treatment as usual on glycemic control and life skills: a randomized clinical trial in adolescents with type 1 diabetes , 2014, Trials.

[231]  L. Rydén,et al.  Intensified insulin-based glycaemic control after myocardial infarction: mortality during 20 year follow-up of the randomised Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction (DIGAMI 1) trial. , 2014, The lancet. Diabetes & endocrinology.

[232]  M. Woodward,et al.  Impact of Visit-to-Visit Glycemic Variability on the Risks of Macrovascular and Microvascular Events and All-Cause Mortality in Type 2 Diabetes: The ADVANCE Trial , 2014, Diabetes Care.

[233]  T. Peto,et al.  Prevalence and associations of diabetic retinopathy in a large cohort of prediabetic subjects: the Gutenberg Health Study. , 2014, Journal of diabetes and its complications.

[234]  B. Zinman,et al.  Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™) , 2014, Cardiovascular Diabetology.

[235]  E. Amsterdam,et al.  Association of elevated fasting glucose with lower patency and increased major adverse limb events among patients with diabetes undergoing infrapopliteal balloon angioplasty , 2014, Vascular medicine.

[236]  K. Khunti,et al.  Effect of Early Multifactorial Therapy Compared With Routine Care on Microvascular Outcomes at 5 Years in People With Screen-Detected Diabetes: A Randomized Controlled Trial , 2014, Diabetes Care.

[237]  M. Mack,et al.  Five-Year Outcomes in Patients With Left Main Disease Treated With Either Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting in the Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery Trial , 2014, Circulation.

[238]  G. Roglić,et al.  Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study. , 2014, The lancet. Diabetes & endocrinology.

[239]  A. Hoes,et al.  Effectiveness of a preventive cardiology programme for high CVD risk persistent smokers: the EUROACTION PLUS varenicline trial. , 2014, European heart journal.

[240]  A. Vaag,et al.  Association of heart failure severity with risk of diabetes: a Danish nationwide cohort study , 2014, Diabetologia.

[241]  Carin M. Van Gelder,et al.  One-year outcomes of out-of-hospital administration of intravenous glucose, insulin, and potassium (GIK) in patients with suspected acute coronary syndromes (from the IMMEDIATE [Immediate Myocardial Metabolic Enhancement During Initial Assessment and Treatment in Emergency Care] Trial). , 2014, The American journal of cardiology.

[242]  Alan Bernjak,et al.  Risk of Cardiac Arrhythmias During Hypoglycemia in Patients With Type 2 Diabetes and Cardiovascular Risk , 2014, Diabetes.

[243]  R. Brook,et al.  Relations of Change in Plasma Levels of LDL‐C, Non‐HDL‐C and apoB With Risk Reduction From Statin Therapy: A Meta‐Analysis of Randomized Trials , 2014, Journal of the American Heart Association.

[244]  P. de Rango,et al.  Diabetes and abdominal aortic aneurysms. , 2014, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[245]  C. Held,et al.  Biomarkers in Relation to the Effects of Ticagrelor in Comparison With Clopidogrel in Non–ST-Elevation Acute Coronary Syndrome Patients Managed With or Without In-Hospital Revascularization: A Substudy From the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) Trial , 2014, Circulation.

[246]  V. Aboyans,et al.  [2014 ESC Guidelines on the diagnosis and treatment of aortic diseases]. , 2014, Kardiologia polska.

[247]  D. Nathan,et al.  The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: Overview , 2013, Diabetes Care.

[248]  B. Zinman,et al.  Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: Advances and Contributions , 2013, Diabetes.

[249]  William S. Yancy,et al.  Nutrition Therapy Recommendations for the Management of Adults With Diabetes , 2013, Diabetes Care.

[250]  R. Prager,et al.  PONTIAC (NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease): a prospective randomized controlled trial. , 2013, Journal of the American College of Cardiology.

[251]  Jeroen J. Bax,et al.  2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. , 2013, European heart journal.

[252]  Craig Wilson,et al.  Alogliptin after acute coronary syndrome in patients with type 2 diabetes. , 2013, The New England journal of medicine.

[253]  Deepak L. Bhatt,et al.  Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. , 2013, The New England journal of medicine.

[254]  Yasunori Ueda,et al.  The utility of ultrasonic tissue characterization of carotid plaque in the prediction of cardiovascular events in diabetic patients. , 2013, Atherosclerosis.

[255]  S. Engel,et al.  Sulphonylureas and risk of cardiovascular disease: systematic review and meta‐analysis , 2013, Diabetic medicine : a journal of the British Diabetic Association.

[256]  F. Hu,et al.  Effect of the Mediterranean diet on blood pressure in the PREDIMED trial: results from a randomized controlled trial , 2013, BMC Medicine.

[257]  Marina Scavini,et al.  Intensive Structured Self-Monitoring of Blood Glucose and Glycemic Control in Noninsulin-Treated Type 2 Diabetes , 2013, Diabetes Care.

[258]  S. Yusuf,et al.  Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial. , 2013, European heart journal.

[259]  S. Hazen,et al.  Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience. , 2013, American heart journal.

[260]  Lluís Mont,et al.  2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). , 2013, European heart journal.

[261]  B. Uretsky,et al.  Effectiveness of Percutaneous Coronary Intervention With Drug‐Eluting Stents Compared With Bypass Surgery in Diabetics With Multivessel Coronary Disease: Comprehensive Systematic Review and Meta‐analysis of Randomized Clinical Data , 2013, Journal of the American Heart Association.

[262]  J. Spertus,et al.  Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina). , 2013, Journal of the American College of Cardiology.

[263]  A. Scheen,et al.  Metformin revisited: a critical review of the benefit-risk balance in at-risk patients with type 2 diabetes. , 2013, Diabetes & metabolism.

[264]  M. Mack,et al.  Treatment of complex coronary artery disease in patients with diabetes: 5-year results comparing outcomes of bypass surgery and percutaneous coronary intervention in the SYNTAX trial. , 2013, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[265]  J. Saaddine,et al.  Achievement of goals in U.S. diabetes care, 1999-2010. , 2013, The New England journal of medicine.

[266]  A. Scheen.  Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease , 2013, Expert opinion on drug metabolism & toxicology.

[267]  Alexander Turchin,et al.  Accuracy of Electronically Reported “Meaningful Use” Clinical Quality Measures , 2013, Annals of Internal Medicine.

[268]  M. Petretta,et al.  Incremental prognostic value of stress myocardial perfusion imaging in asymptomatic diabetic patients. , 2013, Atherosclerosis.

[269]  I. Gustafsson,et al.  Abnormal glucose metabolism is associated with reduced left ventricular contractile reserve and exercise intolerance in patients with chronic heart failure. , 2013, European heart journal cardiovascular Imaging.

[270]  Daniala L. Weir,et al.  Comparative Safety and Effectiveness of Metformin in Patients With Diabetes Mellitus and Heart Failure: Systematic Review of Observational Studies Involving 34 000 Patients , 2013, Circulation. Heart failure.

[271]  D. Reda,et al.  Percutaneous coronary intervention versus coronary bypass surgery in United States veterans with diabetes. , 2013, Journal of the American College of Cardiology.

[272]  Antonio Colombo,et al.  Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial , 2013, The Lancet.

[273]  G. Bray,et al.  Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. , 2013, The New England journal of medicine.

[274]  G. Schuler,et al.  Comparison of bare-metal stenting with minimally invasive bypass surgery for stenosis of the left anterior descending coronary artery: 10-year follow-up of a randomized trial. , 2013, JACC. Cardiovascular interventions.

[275]  Akshay S. Desai,et al.  Strategies for multivessel revascularization in patients with diabetes. , 2012, The New England journal of medicine.

[276]  V. Aboyans,et al.  Measurement and interpretation of the ankle-brachial index: a scientific statement from the American Heart Association. , 2012, Circulation.

[277]  André Scheen,et al.  RECOMMANDATIONS 2012 EN DIABÉTOLOGIE: Prise en charge de l'hyperglycémie dans le diabète de type 2: une approche centrée sur le patient , 2012 .

[278]  J. Gallacher,et al.  C-reactive protein, fibrinogen, and cardiovascular disease prediction. , 2012, The New England journal of medicine.

[279]  H. Heidbuchel,et al.  Importance of characteristics and modalities of physical activity and exercise in the management of cardiovascular health in individuals with cardiovascular risk factors: recommendations from the EACPR (Part II) , 2012, European journal of preventive cardiology.

[280]  J. Dillinger,et al.  Biological efficacy of twice daily aspirin in type 2 diabetic patients with coronary artery disease. , 2012, American heart journal.

[281]  U. Nöthlings,et al.  Physical Activity and Mortality in Individuals With Diabetes Mellitus: A Prospective Study and Meta-analysis. , 2012, Archives of internal medicine.

[282]  Lawrence A Leiter,et al.  Intensive and Standard Blood Pressure Targets in Patients With Type 2 Diabetes Mellitus: Systematic Review and Meta-analysis. , 2012, Archives of internal medicine.

[283]  H. Lutsep,et al.  Restenosis after carotid artery stenting and endarterectomy: a secondary analysis of CREST, a randomised controlled trial , 2012, The Lancet Neurology.

[284]  Giel Nijpels,et al.  Common carotid intima-media thickness measurements in cardiovascular risk prediction: a meta-analysis. , 2012, JAMA.

[285]  R. Collins,et al.  The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. , 2012, Lancet.

[286]  S. Yusuf,et al.  n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. , 2012, The New England journal of medicine.

[287]  Salim Yusuf,et al.  Basal insulin and cardiovascular and other outcomes in dysglycemia. , 2012, The New England journal of medicine.

[288]  A. Fretheim,et al.  Group based diabetes self-management education compared to routine treatment for people with type 2 diabetes mellitus. A systematic review with meta-analysis , 2012, BMC Health Services Research.

[289]  M. Sabatine,et al.  An invasive or conservative strategy in patients with diabetes mellitus and non-ST-segment elevation acute coronary syndromes: a collaborative meta-analysis of randomized trials. , 2012, Journal of the American College of Cardiology.

[290]  F. Santilli,et al.  The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low‐dose aspirin in patients with and without diabetes , 2012, Journal of thrombosis and haemostasis : JTH.

[291]  M. Huijberts,et al.  Associations Between the Ankle-Brachial Index and Cardiovascular and All-Cause Mortality Are Similar in Individuals Without and With Type 2 Diabetes , 2012, Diabetes Care.

[292]  Lu Gao,et al.  Carotid intima-media thickness progression to predict cardiovascular events in the general population (the PROG-IMT collaborative project): a meta-analysis of individual participant data , 2012, The Lancet.

[293]  F. Rutten,et al.  High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes , 2012, Diabetologia.

[294]  Chia-Ing Li,et al.  Variation of fasting plasma glucose: a predictor of mortality in patients with type 2 diabetes. , 2012, The American journal of medicine.

[295]  N. Brown,et al.  Differential Effects of Nebivolol and Metoprolol on Insulin Sensitivity and Plasminogen Activator Inhibitor in the Metabolic Syndrome , 2012, Hypertension.

[296]  M. Bertolet,et al.  Impact of Completeness of Revascularization on Long-Term Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus: Results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) , 2012, Circulation. Cardiovascular interventions.

[297]  J. Kastelein,et al.  Statin use during pregnancy: a systematic review and meta-analysis , 2012, Expert review of cardiovascular therapy.

[298]  Deepak L. Bhatt,et al.  Antiplatelet Therapy and Proton Pump Inhibition: Clinician Update , 2012, Circulation.

[299]  J. Wylie-Rosett,et al.  Macronutrients, Food Groups, and Eating Patterns in the Management of Diabetes , 2012, Diabetes Care.

[300]  Jeroen J. Bax,et al.  Association Between Diffuse Myocardial Fibrosis by Cardiac Magnetic Resonance Contrast-Enhanced T1 Mapping and Subclinical Myocardial Dysfunction in Diabetic Patients: A Pilot Study , 2012, Circulation. Cardiovascular imaging.

[301]  M. Holmes-Rovner,et al.  Interventions for providers to promote a patient-centred approach in clinical consultations. , 2002, The Cochrane database of systematic reviews.

[302]  Katharina Stibrant Sunnerhagen,et al.  Person-Centered Care — Ready for Prime Time , 2011, European journal of cardiovascular nursing : journal of the Working Group on Cardiovascular Nursing of the European Society of Cardiology.

[303]  J. McMurray,et al.  Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: evidence from a 37,229 patient meta-analysis. , 2011, American heart journal.

[304]  Jeremy T. Wright,et al.  Association of Imaging Markers of Myocardial Fibrosis With Metabolic and Functional Disturbances in Early Diabetic Cardiomyopathy , 2011, Circulation. Cardiovascular imaging.

[305]  G. Stone,et al.  Percutaneous coronary intervention versus coronary artery bypass graft surgery in left main coronary artery disease: a meta-analysis of randomized clinical data. , 2011, Journal of the American College of Cardiology.

[306]  A. Nitenberg,et al.  Transthoracic echocardiographic abnormalities in asymptomatic diabetic patients: association with microalbuminuria and silent coronary artery disease. , 2011, Diabetes & metabolism.

[307]  M. Budoff,et al.  Impact of Subclinical Atherosclerosis on Cardiovascular Disease Events in Individuals With Metabolic Syndrome and Diabetes , 2011, Diabetes Care.

[308]  P. Hjemdahl,et al.  Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro- or macrovascular complications , 2011, Thrombosis and Haemostasis.

[309]  O. Shirihai,et al.  Altered Mitochondrial Dynamics Contributes to Endothelial Dysfunction in Diabetes Mellitus , 2011, Circulation.

[310]  L. Heinemann,et al.  Oral glucose tolerance test and HbA1c for diagnosis of diabetes in patients undergoing coronary angiography the Silent Diabetes Study , 2011, Diabetologia.

[311]  Paul Welsh,et al.  Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. , 2011, JAMA.

[312]  S. Bangalore,et al.  Blood Pressure Targets in Subjects With Type 2 Diabetes Mellitus/Impaired Fasting Glucose: Observations From Traditional and Bayesian Random-Effects Meta-Analyses of Randomized Trials , 2011, Circulation.

[313]  P. Wilson,et al.  Post Hoc Subgroup Analysis of the HEART2D Trial Demonstrates Lower Cardiovascular Risk in Older Patients Targeting Postprandial Versus Fasting/Premeal Glycemia , 2011, Diabetes Care.

[314]  T. Wadden,et al.  Benefits of Modest Weight Loss in Improving Cardiovascular Risk Factors in Overweight and Obese Individuals With Type 2 Diabetes , 2011, Diabetes Care.

[315]  P. Allebeck,et al.  Type 2 diabetes incidence and socio-economic position: a systematic review and meta-analysis. , 2011, International journal of epidemiology.

[316]  M. Briel,et al.  Intensive statin therapy compared with moderate dosing for prevention of cardiovascular events: a meta-analysis of >40 000 patients. , 2011, European heart journal.

[317]  Daniel Umpierre,et al.  Physical activity advice only or structured exercise training and association with HbA1c levels in type 2 diabetes: a systematic review and meta-analysis. , 2011, JAMA.

[318]  G. Mancia,et al.  Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and diabetes: a meta-analysis of placebo-controlled clinical trials. , 2011, American journal of hypertension.

[319]  P. Grant,et al.  Inflammation and thrombosis in diabetes , 2011, Thrombosis and Haemostasis.

[320]  Adrian V. Hernández,et al.  Thiazolidinediones and Risk of Heart Failure in Patients with or at High Risk of Type 2 Diabetes Mellitus , 2011, American journal of cardiovascular drugs : drugs, devices, and other interventions.

[321]  D. Panagiotakos,et al.  The effect of Mediterranean diet on metabolic syndrome and its components: a meta-analysis of 50 studies and 534,906 individuals. , 2011, Journal of the American College of Cardiology.

[322]  Yves Cottin,et al.  Prevalence, incidence, predictive factors and prognosis of silent myocardial infarction: a review of the literature. , 2011, Archives of cardiovascular diseases.

[323]  C. Bhamidipati,et al.  Superiority of moderate control of hyperglycemia to tight control in patients undergoing coronary artery bypass grafting. , 2011, The Journal of thoracic and cardiovascular surgery.

[324]  V. Rigalleau,et al.  Detection of silent myocardial ischemia in asymptomatic patients with diabetes: results of a randomized trial and meta-analysis assessing the effectiveness of systematic screening , 2011, Trials.

[325]  J. McMurray,et al.  Eplerenone in patients with systolic heart failure and mild symptoms. , 2011, The New England journal of medicine.

[326]  C. Yeh,et al.  A Study on Efficacy of Empowerment Training among Diabetes Patients , 2011 .

[327]  Jeroen J. Bax,et al.  Multimodality imaging in diabetic heart disease. , 2011, Current problems in cardiology.

[328]  Neil M. Johannsen,et al.  Effects of aerobic and resistance training on hemoglobin A1c levels in patients with type 2 diabetes: a randomized controlled trial. , 2010, JAMA.

[329]  R. Collins,et al.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.

[330]  T. Krahn,et al.  Insulin resistance and glycemic abnormalities are associated with deterioration of left ventricular diastolic function: a cross-sectional study , 2010, Cardiovascular diabetology.

[331]  Yun-Tao Zhao,et al.  Comparison of glucose-insulin-potassium and insulin-glucose as adjunctive therapy in acute myocardial infarction: a contemporary meta-analysis of randomised controlled trials , 2010, Heart.

[332]  H. Huikuri,et al.  Sudden cardiac death after myocardial infarction in patients with type 2 diabetes. , 2010, Heart rhythm.

[333]  R. Heine,et al.  HbA1c and mean blood glucose show stronger associations with cardiovascular disease risk factors than do postprandial glycaemia or glucose variability in persons with diabetes: the A1C-Derived Average Glucose (ADAG) study , 2010, Diabetologia.

[334]  I. Shimomura,et al.  The Influence of Glycemic Control on the Prognosis of Japanese Patients Undergoing Percutaneous Transluminal Angioplasty for Critical Limb Ischemia , 2010, Diabetes Care.

[335]  P. Valensi,et al.  A large proportion of prediabetes and diabetes goes undiagnosed when only fasting plasma glucose and/or HbA1c are measured in overweight or obese patients. , 2010, Diabetes & metabolism.

[336]  S. Stevens,et al.  Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial , 2010, European heart journal.

[337]  J. Danesh,et al.  Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. , 2010, Lancet.

[338]  R. Arora,et al.  Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus--a pooled meta-analysis of randomized placebo-controlled clinical trials. , 2010, International journal of cardiology.

[339]  J. Coresh,et al.  The Association of Hemoglobin A1c With Incident Heart Failure Among People Without Diabetes: The Atherosclerosis Risk in Communities Study , 2010, Diabetes.

[340]  W. Ambrosius,et al.  Epidemiologic Relationships Between A1C and All-Cause Mortality During a Median 3.4-Year Follow-up of Glycemic Treatment in the ACCORD Trial , 2010, Diabetes Care.

[341]  John B Buse,et al.  Effects of combination lipid therapy in type 2 diabetes mellitus. , 2010, The New England journal of medicine.

[342]  Kevin A Peterson,et al.  Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus , 2011 .

[343]  M. Laakso,et al.  Effect of nateglinide on the incidence of diabetes and cardiovascular events. , 2010, The New England journal of medicine.

[344]  M. Laakso,et al.  Effect of valsartan on the incidence of diabetes and cardiovascular events. , 2010, The New England journal of medicine.

[345]  R. Wachter,et al.  Association of glucose metabolism with diastolic function along the diabetic continuum , 2010, Diabetologia.

[346]  J. Fleg,et al.  Effects of Cardiac Autonomic Dysfunction on Mortality Risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial , 2010, Diabetes Care.

[347]  G. Simonetti,et al.  Long-Term Outcomes of Diabetic Patients With Critical Limb Ischemia Followed in a Tertiary Referral Diabetic Foot Clinic , 2010, Diabetes Care.

[348]  Jeroen J. Bax,et al.  Myocardial Steatosis and Biventricular Strain and Strain Rate Imaging in Patients With Type 2 Diabetes Mellitus , 2010, Circulation.

[349]  Yasuo Ohashi,et al.  Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials , 2010, The Lancet.

[350]  G. Angelini,et al.  Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial. , 2010, Journal of the American College of Cardiology.

[351]  B. Bozkurt,et al.  Comparison of patients with heart failure and preserved left ventricular ejection fraction among those with versus without diabetes mellitus. , 2010, The American journal of cardiology.

[352]  C. Scott,et al.  The development of heart failure in patients with diabetes mellitus and pre-clinical diastolic dysfunction a population-based study. , 2010, Journal of the American College of Cardiology.

[353]  D. Rader,et al.  Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance. , 2010, The American journal of cardiology.

[354]  J. Pankow,et al.  Diabetes and the risk of sudden cardiac death, the Atherosclerosis Risk in Communities study , 2010, Acta Diabetologica.

[355]  Regina M. Hardison,et al.  The Bypass Angioplasty Revascularization Investigation 2 Diabetes Randomized Trial of Different Treatment Strategies in Type 2 Diabetes Mellitus With Stable Ischemic Heart Disease: Impact of Treatment Strategy on Cardiac Mortality and Myocardial Infarction , 2009, Circulation.

[356]  M. Woodward,et al.  Coffee, decaffeinated coffee, and tea consumption in relation to incident type 2 diabetes mellitus: a systematic review with meta-analysis. , 2009, Archives of internal medicine.

[357]  Antonio Colombo,et al.  Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. , 2009, The New England journal of medicine.

[358]  Jeroen J. Bax,et al.  Findings from left ventricular strain and strain rate imaging in asymptomatic patients with type 2 diabetes mellitus. , 2009, The American journal of cardiology.

[359]  David M Nathan,et al.  10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. , 2009, Lancet.

[360]  R. Benediktsson,et al.  Instruments to tailor care of people with type 2 diabetes. , 2009, Journal of advanced nursing.

[361]  K. Reinier,et al.  Independent Contribution of Diabetes to Increased Prevalence and Incidence of Atrial Fibrillation , 2009, Diabetes Care.

[362]  Claes Held,et al.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.

[363]  Thomas E. Moritz,et al.  Intensive glucose control and macrovascular outcomes in type 2 diabetes , 2009, Diabetologia.

[364]  G. Schuler,et al.  Randomized comparison of minimally invasive direct coronary artery bypass surgery versus sirolimus-eluting stenting in isolated proximal left anterior descending coronary artery stenosis. , 2009, Journal of the American College of Cardiology.

[365]  Maria Mori Brooks,et al.  A randomized trial of therapies for type 2 diabetes and coronary artery disease. , 2009, The New England journal of medicine.

[366]  R. Collins,et al.  Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. , 2009, Lancet.

[367]  N. Sattar,et al.  Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials , 2009, The Lancet.

[368]  Deepak L. Bhatt,et al.  Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial). , 2009, The American journal of cardiology.

[369]  G. Lip,et al.  Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study. , 2009, European heart journal.

[370]  Irl B Hirsch,et al.  Web-based collaborative care for type 1 diabetes: a pilot randomized trial. , 2009, Diabetes technology & therapeutics.

[371]  D. Wald,et al.  Combination Therapy Versus Monotherapy in Reducing Blood Pressure: Meta-analysis on 11,000 Participants from 42 Trials , 2010 .

[372]  G. Hitman,et al.  Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS). , 2009, Clinical chemistry.

[373]  P. Wilson,et al.  Effects of Prandial Versus Fasting Glycemia on Cardiovascular Outcomes in Type 2 Diabetes: The HEART2D trial , 2009, Diabetes Care.

[374]  Sanjay Kaul,et al.  The impact of revascularization on mortality in patients with nonacute coronary artery disease. , 2009, The American journal of medicine.

[375]  Grant D. Huang,et al.  Glucose control and vascular complications in veterans with type 2 diabetes. , 2009, The New England journal of medicine.

[376]  A. Keech,et al.  Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome , 2008, Diabetes Care.

[377]  R. Stolk,et al.  Randomised controlled trial of intensive multifactorial treatment for cardiovascular risk in patients with screen-detected type 2 diabetes: 1-year data from the ADDITION Netherlands study. , 2009, The British journal of general practice : the journal of the Royal College of General Practitioners.

[378]  Anil Jain,et al.  The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis , 2009, Acta Diabetologica.

[379]  Jeroen J. Bax,et al.  Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. , 2008, Journal of the American College of Cardiology.

[380]  Nikolaus Marx,et al.  The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. , 2008, The American journal of cardiology.

[381]  Loki Natarajan,et al.  The association between elevated ankle systolic pressures and peripheral occlusive arterial disease in diabetic and nondiabetic subjects. , 2008, Journal of vascular surgery.

[382]  R. Collins,et al.  The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes , 2008, Journal of hypertension.

[383]  E. Antman,et al.  Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38 , 2008, Circulation.

[384]  Rury R Holman,et al.  Long-term follow-up after tight control of blood pressure in type 2 diabetes. , 2008, The New England journal of medicine.

[385]  R. Holman,et al.  10-year follow-up of intensive glucose control in type 2 diabetes. , 2008, The New England journal of medicine.

[386]  M. Perez,et al.  Isolated disease of the proximal left anterior descending artery comparing the effectiveness of percutaneous coronary interventions and coronary artery bypass surgery. , 2008, JACC. Cardiovascular interventions.

[387]  M. Jardine,et al.  The Relationship between Proteinuria and Coronary Risk: A Systematic Review and Meta-Analysis , 2008, PLoS medicine.

[388]  R. Prager,et al.  NT-proBNP has a high negative predictive value to rule-out short-term cardiovascular events in patients with diabetes mellitus. , 2008, European heart journal.

[389]  E. Tuzcu,et al.  Effect of diabetes on progression of coronary atherosclerosis and arterial remodeling: a pooled analysis of 5 intravascular ultrasound trials. , 2008, Journal of the American College of Cardiology.

[390]  A Hofman,et al.  Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. , 2008, JAMA.

[391]  Michael E. Miller,et al.  Effects of intensive glucose lowering in type 2 diabetes. , 2008, The New England journal of medicine.

[392]  Diederick Grobbee,et al.  Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. , 2008, The New England journal of medicine.

[393]  Karl Swedberg,et al.  Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. , 2008, European heart journal.

[394]  R. Kloner,et al.  Glucose-insulin-potassium for acute myocardial infarction: continuing controversy over cardioprotection. , 2008, Circulation.

[395]  L. Opie.  Metabolic Management of Acute Myocardial Infarction Comes to the Fore and Extends Beyond Control of Hyperglycemia , 2008, Circulation.

[396]  L. Rydén,et al.  Evidence-based medication and revascularization: powerful tools in the management of patients with diabetes and coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart , 2008, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[397]  O. Pedersen,et al.  Effect of a multifactorial intervention on mortality in type 2 diabetes. , 2008, The New England journal of medicine.

[398]  R. Higgins,et al.  Drug-eluting stents vs. coronary-artery bypass grafting in multivessel coronary disease. , 2008, The New England journal of medicine.

[399]  R Peto,et al.  Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. , 2008, Lancet.

[400]  J. Leach,et al.  Guideline Development Group , 2008 .

[401]  J. Cornuz,et al.  Active smoking and the risk of type 2 diabetes: a systematic review and meta-analysis. , 2007, JAMA.

[402]  D. J. Veldhuisen,et al.  Advanced glycation end‐products (AGEs) and heart failure: Pathophysiology and clinical implications , 2007, European journal of heart failure.

[403]  E. Antman,et al.  Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.

[404]  J. Ghali,et al.  Influence of diabetes on cardiac resynchronization therapy with or without defibrillator in patients with advanced heart failure. , 2007, Journal of cardiac failure.

[405]  A. Skene,et al.  Pioglitazone Use and Heart Failure in Patients With Type 2 Diabetes and Preexisting Cardiovascular Disease , 2007, Diabetes Care.

[406]  S. Nissen,et al.  Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. , 2007, The New England journal of medicine.

[407]  A. Skene,et al.  The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. , 2007, Journal of the American College of Cardiology.

[408]  Ara Darzi,et al.  Meta-analysis of minimally invasive internal thoracic artery bypass versus percutaneous revascularisation for isolated lesions of the left anterior descending artery , 2007, BMJ : British Medical Journal.

[409]  D. Betteridge,et al.  Effects of Pioglitazone in Patients With Type 2 Diabetes With or Without Previous Stroke: Results From PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04) , 2007, Stroke.

[410]  L. Rydén,et al.  Diabetes known or newly detected, but not impaired glucose regulation, has a negative influence on 1-year outcome in patients with coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart. , 2006, European heart journal.

[411]  M. Zwahlen,et al.  QTc interval and resting heart rate as long-term predictors of mortality in type 1 and type 2 diabetes mellitus: a 23-year follow-up , 2006, Diabetologia.

[412]  S. Yusuf,et al.  Effect of ramipril on the incidence of diabetes. , 2006, The New England journal of medicine.

[413]  Ali Ahmed,et al.  Effects of Digoxin on Morbidity and Mortality in Diastolic Heart Failure: The Ancillary Digitalis Investigation Group Trial , 2006, Circulation.

[414]  J. Tuomilehto,et al.  Coffee consumption and risk of total and cardiovascular mortality among patients with type 2 diabetes , 2006, Diabetologia.

[415]  Roberto Sega,et al.  Long-Term Risk of Mortality Associated With Selective and Combined Elevation in Office, Home, and Ambulatory Blood Pressure , 2006, Hypertension.

[416]  L. Shaw,et al.  Risk stratification in uncomplicated type 2 diabetes: prospective evaluation of the combined use of coronary artery calcium imaging and selective myocardial perfusion scintigraphy. , 2006, European heart journal.

[417]  Gianni Tognoni,et al.  Aspirin for the Primary Prevention of Cardiovascular Events in Women and Men: A Sex-Specific Meta-Analysis of Randomized Controlled Trials , 2006, JAMA.

[418]  A. Avogaro,et al.  Detection of coronary artery disease in asymptomatic patients with type 2 diabetes mellitus. , 2006, Journal of the American College of Cardiology.

[419]  P. Kowey,et al.  Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies. , 2005, The American journal of cardiology.

[420]  B. Golomb,et al.  Exertional Leg Pain in Patients With and Without Peripheral Arterial Disease , 2005, Circulation.

[421]  B. Estour,et al.  Predictive value of silent myocardial ischemia for cardiac events in diabetic patients: influence of age in a French multicenter study. , 2005, Diabetes care.

[422]  T. Rea,et al.  Diabetes, glucose level, and risk of sudden cardiac death. , 2005, European heart journal.

[423]  Ross T Tsuyuki,et al.  Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. , 2005, Diabetes care.

[424]  J. O’Keefe,et al.  Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. , 2005, Journal of the American College of Cardiology.

[425]  E. Ingelsson,et al.  Insulin resistance and risk of congestive heart failure. , 2005, JAMA.

[426]  R. Giugliano,et al.  U-shaped relationship of blood glucose with adverse outcomes among patients with ST-segment elevation myocardial infarction. , 2005, Journal of the American College of Cardiology.

[427]  Darren K Mcguire,et al.  Association between hyper- and hypoglycaemia and 2 year all-cause mortality risk in diabetic patients with acute coronary events. , 2005, European heart journal.

[428]  P. Hildebrandt,et al.  Prevalence and characteristics of diabetic patients in a chronic heart failure population. , 2005, International journal of cardiology.

[429]  M. Laakso,et al.  Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity , 2005 .

[430]  Vilmundur Gudnason,et al.  The association between glucose abnormalities and heart failure in the population-based Reykjavik study. , 2005, Diabetes care.

[431]  H. Krumholz,et al.  Thiazolidinediones, Metformin, and Outcomes in Older Patients With Diabetes and Heart Failure: An Observational Study , 2005, Circulation.

[432]  E. Faglia,et al.  Risk reduction of cardiac events by screening of unknown asymptomatic coronary artery disease in subjects with type 2 diabetes mellitus at high cardiovascular risk: an open-label randomized pilot study. , 2005, American heart journal.

[433]  P. Deedwania,et al.  Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF. , 2005, American heart journal.

[434]  G. Fonarow,et al.  Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure. , 2005, American heart journal.

[435]  Claude Bouchard,et al.  Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. , 2004, The New England journal of medicine.

[436]  P. Raskin,et al.  Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. , 2004, JAMA.

[437]  Roberto Ferrari,et al.  The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. , 2004, European heart journal.

[438]  James B. Young,et al.  The global epidemiology of heart failure. , 2004, The Medical clinics of North America.

[439]  C. Gullion,et al.  The incidence of congestive heart failure in type 2 diabetes: an update. , 2004, Diabetes care.

[440]  D. DeMets,et al.  Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. , 2004, The New England journal of medicine.

[441]  Julio E. Pérez,et al.  Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitus. , 2004, The American journal of cardiology.

[442]  P. Valensi,et al.  Detecting silent coronary stenoses and stratifying cardiac risk in patients with diabetes: ECG stress test or exercise myocardial scintigraphy? , 2004, Diabetic medicine : a journal of the British Diabetic Association.

[443]  L. Monti,et al.  Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy. , 2003, American heart journal.

[444]  L. Rydén,et al.  Diabetes, insulin resistance, and the metabolic syndrome in patients with acute myocardial infarction without previously known diabetes. , 2003, Diabetes care.

[445]  Karl Swedberg,et al.  Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial , 2003, The Lancet.

[446]  M. Pfeffer,et al.  Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial , 2003, The Lancet.

[447]  A. J. Swerdlow,et al.  Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes , 2003, Diabetologia.

[448]  Paul G Shekelle,et al.  Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. , 2003, Journal of the American College of Cardiology.

[449]  P. Valensi,et al.  Prognosis for coronary stenoses in patients with diabetes and silent myocardial ischemia. , 2003, Diabetes care.

[450]  Duanping Liao,et al.  Lower heart rate variability is associated with the development of coronary heart disease in individuals with diabetes: the atherosclerosis risk in communities (ARIC) study. , 2002, Diabetes.

[451]  D. DeMets,et al.  Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure: Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study , 2002, Circulation.

[452]  A. Hamsten,et al.  Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study , 2002, The Lancet.

[453]  Catherine Sudlow,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[454]  L. Niskanen,et al.  Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project. , 2001, Diabetes care.

[455]  G. Nichols,et al.  Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. , 2001, Diabetes care.

[456]  W. Hermann,et al.  Results from post‐hoc analyses of the CIBIS II trial: effect of bisoprolol in high‐risk patient groups with chronic heart failure , 2001 .

[457]  L. D. Saunders,et al.  Long-term survival in 11,661 patients with multivessel coronary artery disease in the era of stenting: a report from the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease (APPROACH) Investigators. , 2001, American heart journal.

[458]  B V Howard,et al.  The impact of diabetes on left ventricular filling pattern in normotensive and hypertensive adults: the Strong Heart Study. , 2001, Journal of the American College of Cardiology.

[459]  T. Marwick,et al.  Prediction of Mortality by Exercise Echocardiography: A Strategy for Combination With the Duke Treadmill Score , 2001, Circulation.

[460]  D. Singer,et al.  Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. , 2001, JAMA.

[461]  T. Valle,et al.  Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. , 2001, The New England journal of medicine.

[462]  P. Ducimetiere,et al.  New diagnostic criteria for diabetes and coronary artery disease: insights from an angiographic study. , 2001, Journal of the American College of Cardiology.

[463]  V. Froelicher,et al.  Clinical utility of the exercise ECG in patients with diabetes and chest pain. , 2001, Chest.

[464]  P. Poole‐Wilson,et al.  Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial. , 2000, European heart journal.

[465]  John S Yudkin,et al.  Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study , 2000, BMJ : British Medical Journal.

[466]  B. Pitt,et al.  The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure , 2000 .

[467]  Salim Yusuf,et al.  Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients , 2000, The Lancet.

[468]  J. Gardin,et al.  Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. , 2000, Journal of the American College of Cardiology.

[469]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.

[470]  E. Feskens,et al.  Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria , 1999, The Lancet.

[471]  J. Mehlsen,et al.  Serum levels of advanced glycation end products are associated with left ventricular diastolic function in patients with type 1 diabetes. , 1999, Diabetes care.

[472]  L. Køber,et al.  Effect of the angiotensin-converting enzyme inhibitor trandolapril on mortality and morbidity in diabetic patients with left ventricular dysfunction after acute myocardial infarction. Trace Study Group. , 1999, Journal of the American College of Cardiology.

[473]  Christianna S. Williams,et al.  Risk factors for heart failure in the elderly: a prospective community-based study. , 1999, The American journal of medicine.

[474]  O. Pedersen,et al.  Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study , 1999, The Lancet.

[475]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[476]  R. Holman,et al.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.

[477]  R. D'Agostino,et al.  Sudden coronary death in women. , 1998, American heart journal.

[478]  R. Collins,et al.  Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group. , 1998, Circulation.

[479]  L H Kuller,et al.  Incidence of and risk factors for atrial fibrillation in older adults. , 1997, Circulation.

[480]  G. Paolisso,et al.  Congestive heart failure predicts the development of non-insulin-dependent diabetes mellitus in the elderly. The Osservatorio Geriatrico Regione Campania Group. , 1997, Diabetes & metabolism.

[481]  K. Malmberg.  Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus , 1997, BMJ.

[482]  Y. Hong,et al.  Megakaryocyte ploidy and platelet changes in human diabetes and atherosclerosis. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[483]  E. J. Brown,et al.  The effect of digoxin on mortality and morbidity in patients with heart failure. , 1997, The New England journal of medicine.

[484]  D. Clement.  A randomised, blinded, trial of Clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) , 1996 .

[485]  J Herlitz,et al.  Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. , 1995, Journal of the American College of Cardiology.

[486]  K. Yano,et al.  Sudden death, impaired glucose tolerance, and diabetes in Japanese American men. , 1995, Circulation.

[487]  F A Mathewson,et al.  The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. , 1995, The American journal of medicine.

[488]  J. Brown.  Patient-centred medicine: Transforming the clinical method , 1998 .

[489]  T. Chalmers,et al.  Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration , 1994, The Lancet.

[490]  B. Davis,et al.  Uniformity of captopril benefit in the SAVE Study: subgroup analysis. Survival and Ventricular Enlargement Study. , 1994, European heart journal.

[491]  D. Levy,et al.  Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. , 1994, JAMA.

[492]  H. Dargie,et al.  Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Trimetazidine European Multicenter Study Group. , 1994, British journal of clinical pharmacology.

[493]  Walker,et al.  Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients , 1994 .

[494]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[495]  E. J. Brown,et al.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.

[496]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[497]  G. Davı̀,et al.  Thromboxane biosynthesis and platelet function in type II diabetes mellitus. , 1990, The New England journal of medicine.

[498]  D. Grobbee,et al.  The effect on serum cholesterol levels of coffee brewed by filtering or boiling. , 1989, The New England journal of medicine.